Metformin hydrochloride; sitagliptin - Generic Drug Details

What are the generic sources for metformin hydrochloride; sitagliptin and what is the scope of patent protection?

Metformin hydrochloride; sitagliptin is the generic ingredient in five branded drugs marketed by Zydus Lifesciences, Msd Sub Merck, Ph Health, and Sandoz, and is included in six NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for metformin hydrochloride; sitagliptin

US Patents:	2
Tradenames:	5
Applicants:	4
NDAs:	6
Finished Product Suppliers / Packagers:	3
Clinical Trials:	200
DailyMed Link:	metformin hydrochloride; sitagliptin at DailyMed

Recent Clinical Trials for metformin hydrochloride; sitagliptin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE4
Khyber Medical College, Peshawar	PHASE3
Bahria University	PHASE4

See all metformin hydrochloride; sitagliptin clinical trials

Pharmacology for metformin hydrochloride; sitagliptin

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for metformin hydrochloride; sitagliptin

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for metformin hydrochloride; sitagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	SITAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	202388-001	Dec 2, 2025	AB	RX	No	No
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012		RX	Yes	No					Y
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-002	Jul 18, 2024		RX	Yes	No
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Ph Health	SITAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	204144-002	Jun 4, 2025		DISCN	No	No
Ph Health	SITAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	204144-003	Jun 4, 2025		DISCN	No	No
Zydus Lifesciences	ZITUVIMET	metformin hydrochloride; sitagliptin	TABLET;ORAL	216743-002	Nov 3, 2023		RX	Yes	Yes

EU/EMA Drug Approvals for metformin hydrochloride; sitagliptin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Ristfor	sitagliptin, metformin hydrochloride	EMEA/H/C/001235For patients with type-2 diabetes mellitus:Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15
Accord Healthcare S.L.U.	Sitagliptin / Metformin hydrochloride Accord	sitagliptin, metformin hydrochloride	EMEA/H/C/005850For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2022-07-22
Sun Pharmaceutical Industries Europe B.V.	Sitagliptin / Metformin hydrochloride Sun	sitagliptin, metformin hydrochloride	EMEA/H/C/005778For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2023-03-31

Metformin hydrochloride; sitagliptin Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Current Market Dynamics for Metformin Hydrochloride and Sitagliptin?

Metformin hydrochloride and sitagliptin are two leading drugs for type 2 diabetes management. They are often used alone or in combination, influencing their market trajectories.

Market Share and Revenue

As of 2022, metformin remains the most prescribed antidiabetic drug globally, with an estimated market share of over 50% among oral hypoglycemics. Its low cost, extensive clinical history, and efficacy drive continued demand. In the US, the drug's annual sales exceed $1.2 billion, with global revenues surpassing $5 billion.

Sitagliptin, marketed as Januvia by Merck since 2006, holds a significant position as the second most prescribed DPP-4 inhibitor. Its US sales were approximately $3.15 billion in 2022, with global sales reaching $4.5 billion. The drug's popularity stems from its convenience and tolerability, especially in combination therapies.

Manufacturing and Supply Dynamics

Metformin's generics dominate production, with multiple manufacturers worldwide controlling supply chains. Recent years have seen increased manufacturing capacity to meet rising demand, especially in emerging markets.

Sitagliptin remains protected under patent until 2027 in key markets. Post-patent expiration, generic versions are expected to proliferate, possibly leading to price reductions and increased accessibility.

Competitive Landscape

The antidiabetic market features several drug classes: SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and DPP-4 inhibitors. While metformin maintains dominance as the first-line therapy, sitagliptin competes with other DPP-4 inhibitors like linagliptin and saxagliptin.

The combination of metformin and sitagliptin is commonly prescribed, forming a significant segment that benefits from fixed-dose formulations.

Regulatory and Policy Factors

Global initiatives favor cost-effective treatments. Regulatory agencies in low- and middle-income countries approve biosimilars and generics rapidly to enhance access. In contrast, patent protections in high-income markets extend exclusivity, delaying generic competition.

In 2020, the EMA approved a biosimilar of sitagliptin, though market penetration remains limited due to existing patent protections.

What Are the Financial Trajectories for Both Drugs?

Revenue Trends and Forecasts

Drug	2022 US Sales (USD billion)	2023-2027 Compound Annual Growth Rate (CAGR)	Notes
Metformin	Over 1.2	1.5%	Stabilized, driven by generic manufacturing
Sitagliptin	3.15	4%	Slight decline expected post-patent expiration

The growth of metformin remains steady, supported by its low cost and broad usage, especially in developing countries. Sitagliptin's revenue growth is projected to stabilize; however, post-2027, generic versions could reduce prices and revenues.

R&D and Pipeline Outlook

Both drugs currently face limited ongoing R&D investments given their established efficacy. However, combination formulations and biosimilars are areas of innovation.

Large pharmaceutical firms focus on newer drug classes, such as SGLT2 inhibitors, which threaten the market share of older drugs. Despite this, metformin and sitagliptin are expected to retain significant markets due to established safety profiles.

Pricing Dynamics

Prices for metformin remain low due to generic competition. Sitagliptin's branded prices are around $300-$400 per month; generics are priced at about 20-30% less. Price erosion accelerates after patent expiration.

Market Risks and Opportunities

Risks include patent challenges, generic market penetration, and competition from novel therapies. Opportunities involve expanding use in early intervention, combination therapies, and expanding access in emerging markets.

What Are the Key Takeaways for Stakeholders?

• Metformin maintains dominance through low cost and extensive clinical data, with stable revenue and continued growth in emerging markets.
• Sitagliptin’s revenue is stable currently but will likely decline post-2027 due to patent expiry and generic entry.
• Market dynamics favor generic manufacturing, especially for metformin, with ongoing potential in combination therapies.
• Regulatory policies heavily influence market movements; biosimilars could reshape the landscape in upcoming years.
• Innovation focus shifts toward newer mechanisms (SGLT2 inhibitors, GLP-1 receptor agonists), but metformin and sitagliptin will sustain their roles due to established efficacy and tolerability.

FAQs

1. When will generic versions of sitagliptin become widely available?
Post-2027, when the patent expires in key markets like the US and EU, generics are expected to enter the market, leading to price declines.

2. How does the efficacy of metformin and sitagliptin compare?
Metformin reduces glucose production in the liver; sitagliptin enhances incretin levels. Both are effective, but combination therapy provides additive benefits.

3. Are there safety concerns restricting growth?
Metformin has rare but serious side effects like lactic acidosis. Sitagliptin is generally well-tolerated but has been scrutinized for potential risks of pancreatitis.

4. What opportunities exist for investment?
Focus on biosimilar development, combination therapies, and expanding access in emerging markets.

5. How will new therapies impact the market?
While newer drugs offer benefits like weight loss and cardiovascular risk reduction, metformin and sitagliptin will sustain significant markets due to affordability and clinical familiarity.

---

References

1. IQVIA, 2022 Pharmaceutical Market Data.
2. Merck, 2022 Annual Report.
3. GlobalData, Diabetes Drug Market Forecasts, 2023.
4. European Medicines Agency, 2020 Biosimilar Approvals.
5. FDA, Patent Status of Sitagliptin, 2022.